文献速递炎症性肠病消化内镜

克罗恩病维持治疗需更高细胞因子阻断剂浓度以实现小肠黏膜愈合

Higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's disease.
PubMed 文献 · Aliment Pharmacol Ther · 2021-07-29

一项单中心横断面研究纳入143例接受英夫利西单抗、阿达木单抗或乌司奴单抗维持治疗的克罗恩病患者,通过球囊辅助小肠镜和血清药物浓度检测,发现小肠内镜缓解率显著低于结肠,且实现小肠内镜缓解所需药物浓度更高。

要点

  • 小肠病变内镜缓解率显著低于结肠病变(P<0.01)。
  • 英夫利西单抗、阿达木单抗、乌司奴单抗浓度分别>5、14、4 µg/mL时小肠缓解可能性更高。
  • 细胞因子阻断剂对小肠炎症的疗效低于结肠炎症。

核心结论

  • 细胞因子阻断剂治疗对小肠炎症的疗效低于结肠炎症,实现小肠内镜缓解需要更高的血清药物浓度。

研究设计与样本

  • 单中心横断面研究,纳入2018年4月至2020年5月接受维持性细胞因子阻断剂治疗的克罗恩病患者143例,其中英夫利西单抗66例、阿达木单抗44例、乌司奴单抗33例。

主要发现

  • 小肠病变内镜缓解率显著低于结肠病变(P<0.01)。
  • 英夫利西单抗、阿达木单抗、乌司奴单抗浓度分别>5、14、4 µg/mL的患者,小肠内镜缓解可能性分别约为其他患者的5.3倍、9.4倍和14.7倍。
  • 每种药物达到小肠内镜缓解的患者平均药物浓度高于仅结肠缓解或任何活动性疾病的患者。

关键数值与推荐

  • 英夫利西单抗浓度>5 µg/mL与小肠内镜缓解相关(OR约5.3)。
  • 阿达木单抗浓度>14 µg/mL与小肠内镜缓解相关(OR约9.4)。
  • 乌司奴单抗浓度>4 µg/mL与小肠内镜缓解相关(OR约14.7)。

临床怎么用

  • 对克罗恩病小肠病变患者,维持治疗时可能需要更高的细胞因子阻断剂血清浓度以实现内镜缓解。

局限性

  • 单中心横断面研究,样本量有限,因果关系不能确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Several studies have reported a positive correlation between serum drug concentrations and endoscopic remission in patients with Crohn's disease. AIM: To examine the association between the concentrations of cytokine blockers (infliximab, adalimumab and ustekinumab) and endoscopic remission of small bowel lesions. METHOD: This was a cross-sectional study conducted at a single tertiary referral centre. Patients with Crohn's disease who received maintenance cytokine blocker therapy were recruited from April 2018 to May 2020. We performed balloon-assisted enteroscopy and collected serum samples to measure drug concentrations. The primary endpoint was the relationship between the concentrations of cytokine blockers and endoscopic remission in the small bowel. RESULTS: We enrolled 143 patients, 66, 44 and 33 of whom were receiving infliximab, adalimumab and ustekinumab, respectively. Enteroscopic findings showed that the rate of endoscopic remission of small bowel lesions was significantly lower than that of colonic lesions (P < 0.01). For each agent, the mean drug concentration in patients exhibiting endoscopic remission in the small bowel was higher than that observed in patients with endoscopic remission in the colon (but not in the small bowel) or with any active disease (either in the small bowel, colon or both). Patients with infliximab, adalimumab and ustekinumab concentrations >5, 14 and 4 µg/mL were nearly 5.3-, 9.4- and 14.7-times more likely to exhibit endoscopic remission of the small bowel, respectively. CONCLUSIONS: Cytokine blocker treatment was less efficacious for small bowel inflammation than colonic inflammation. Higher serum concentrations were needed to achieve endoscopic remission of small bowel lesions.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Takenaka K, Kawamoto A, Hibiya S, et al. Higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's disease. Aliment Pharmacol Ther. 2021. PMID: 34323301. doi:10.1111/apt.16551

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。